OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Hematology & Oncology is 94. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity	692
Targeting the Wnt/β-catenin signaling pathway in cancer	651
Nanomaterials for cancer therapy: current progress and perspectives	500
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19	483
EZH2: a novel target for cancer treatment	456
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer	373
NK cell-based cancer immunotherapy: from basic biology to clinical development	321
Next generation of immune checkpoint inhibitors and beyond	304
Regulation of PD-L1 expression in the tumor microenvironment	292
Roles of METTL3 in cancer: mechanisms and therapeutic targeting	277
cGAS-STING, an important pathway in cancer immunotherapy	260
Challenges and advances in clinical applications of mesenchymal stromal cells	256
Cancer vaccines as promising immuno-therapeutics: platforms and current progress	240
RNA sequencing: new technologies and applications in cancer research	237
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)	233
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy	231
Isolation and characterization of exosomes for cancer research	217
Combination strategies to maximize the benefits of cancer immunotherapy	216
Dendritic cell biology and its role in tumor immunotherapy	210
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy	207
Immunosenescence: a key player in cancer development	206
Targeting mutant p53 for cancer therapy: direct and indirect strategies	206
Novel therapies emerging in oncology to target the TGF-β pathway	203
Targeting hypoxic tumor microenvironment in pancreatic cancer	199
Neutrophils in cancer carcinogenesis and metastasis	198

Emerging role of exosomes in cancer progression and tumor microenvironment remodeling	194
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis	194
Recent advances in CAR-T cell engineering	192
Applications of single-cell sequencing in cancer research: progress and perspectives	187
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells	186
Liquid biopsy: current technology and clinical applications	183
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response	181
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)	179
Recent advances in therapeutic strategies for triple-negative breast cancer	179
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions	178
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy	169
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research	169
Oncolytic viruses for cancer immunotherapy	165
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma	163
Emerging therapeutic agents for advanced non-small cell lung cancer	161
RNA-binding proteins in tumor progression	157
Targeting CD47 for cancer immunotherapy	155
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study	155
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	151
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019	146
Targeting MCL-1 in cancer: current status and perspectives	146
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway	144
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti	143
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy	142
MEK inhibitors for the treatment of non-small cell lung cancer	139
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	138
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets	137
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	133
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies	132
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target	131
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update	131
Antibody–drug conjugates in solid tumors: a look into novel targets	131
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends	130
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019	128
HMGB1 in inflammation and cancer	128
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment	127
Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis	127
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape	123
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy	122
Modeling neoplastic disease with spheroids and organoids	122
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1	122
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy	116
XPO1-dependent nuclear export as a target for cancer therapy	116
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin	115
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies	115
Exploring immunotherapy in colorectal cancer	114
The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017	112
Role of lysosomes in physiological activities, diseases, and therapy	110
Targeting autophagy to overcome drug resistance: further developments	110
Emerging agents that target signaling pathways in cancer stem cells	110

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy	108
Mesenchymal stem/stromal cells in cancer therapy	107
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential	107
The management of metastatic GIST: current standard and investigational therapeutics	107
How to select IgG subclasses in developing anti-tumor therapeutic antibodies	107
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies	106
tRNA-derived RNA fragments in cancer: current status and future perspectives	106
BCMA-targeted immunotherapy for multiple myeloma	105
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies	104
Emerging agents and regimens for AML	103
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands	103
The potential role of N7-methylguanosine (m7G) in cancer	98
Targeting Akt in cancer for precision therapy	98
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions	98
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation	97
Emerging strategies to target RAS signaling in human cancer therapy	96
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward	95
Gene modification strategies for next-generation CAR T cells against solid cancers	94
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	94